Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 12,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $53.49, for a total transaction of $668,625.00. Following the completion of the transaction, the insider now owns 169,721 shares in the company, valued at $9,078,376.29. This trade represents a 6.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Timothy Rolph also recently made the following trade(s):

• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $55.04, for a total transaction of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $43.43, for a total transaction of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.03, for a total transaction of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $35.88, for a total transaction of $224,250.00.

Akero Therapeutics Stock Up 0.8%

NASDAQ AKRO traded up $0.43 on Monday, hitting $54.71. 2,271,173 shares of the stock were exchanged, compared to its average volume of 994,920. The company has a 50-day moving average price of $42.31 and a 200-day moving average price of $39.64. Akero Therapeutics, Inc. has a fifty-two week low of $21.02 and a fifty-two week high of $58.40. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market cap of $4.36 billion, a PE ratio of -14.59 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91. Sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AKRO has been the subject of a number of analyst reports. Bank of America increased their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, May 27th. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Citigroup reduced their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics has a consensus rating of “Buy” and an average target price of $82.50.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers grew its stake in Akero Therapeutics by 4.7% during the first quarter. Rhumbline Advisers now owns 110,687 shares of the company’s stock worth $4,481,000 after buying an additional 5,001 shares during the period. Strs Ohio bought a new position in shares of Akero Therapeutics in the 1st quarter worth about $510,000. Intech Investment Management LLC lifted its position in shares of Akero Therapeutics by 54.4% in the 1st quarter. Intech Investment Management LLC now owns 58,522 shares of the company’s stock worth $2,369,000 after buying an additional 20,620 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Akero Therapeutics by 53.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 109,909 shares of the company’s stock worth $4,449,000 after buying an additional 38,458 shares during the last quarter. Finally, Woodline Partners LP increased its stake in shares of Akero Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 480,736 shares of the company’s stock valued at $19,460,000 after purchasing an additional 100,769 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.